Biogen stock sinks after Alzheimer's drug trial data fails to impress investors
The mid-stage study missed its primary goal, and the drug's lowest dose outperformed higher doses in ways the company cannot yet explain
Read the full articleYou might also wanna read
Johnson & Johnson posted stronger-than-expected earnings and raised its full-year outlook
Quartz·1d ago
Q32 Bio stock soared after its alopecia drug cleared a key clinical bar
Quartz·2d ago
Trump Media is selling Wall Street faster access to Trump's market-moving posts
Quartz·5h ago
NTSB says Tesla driver floored the accelerator to override self-driving in fatal Texas crash
Quartz·12h ago
General Mills is recalling nearly 736,000 Pillsbury bread rolls over possible glass
Quartz·12h ago
Starbucks holiday creamers are already hitting grocery stores in the middle of summer
Quartz·12h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.